BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2014

View Archived Issues

Alzheimer's disease organizations fund drug repurposing studies

Read More

Scientists at M2i Development disclose novel diagnostic agents

Read More

Array BioPharma grants Oncothyreon exclusive license to ONT-380

Read More

Galapagos selects GLPG-2222 as part of its triple combination therapy for cystic fibrosis

Read More

Alnylam initiates phase III trial of revusiran in transthyretin-mediated amyloidotic cardiomyopathy

Read More

Novel JAK2 inhibitor NVP-CHZ868 displays potent activity in vitro and in murine MPN models

Read More

Hutchison MediPharma initiates phase III trial of fruquintinib in colorectal cancer

Read More

Inhibition of EZH2 leads to tumor growth inhibition in B-cell lymphoma cell lines

Read More

Study describes levels of biomarker of brain insulin resistance in hippocampal regions

Read More

Animal model of osteochondromagenesis highlights role of NFATc1

Read More

Kolltan Pharmaceuticals describes anti-SCFR monoclonal antibody

Read More

Antitumor activity seen with HER2-T-cell-dependent bispecific antibody developed at Genentech

Read More

BioCryst begins phase I trial of BCX-4430 for hemorrhagic fever viruses

Read More

Synageva BioPharma confirms active IND application for SBC-103

Read More

Novel CXCR-7 modulators disclosed by Actelion Pharmaceuticals

Read More

Cephalon divulges novel ALK inhibitors for cancer

Read More

Taiho Pharmaceutical patents novel compounds for urinary incontinence

Read More

Teijin Pharma reports new XO inhibitors

Read More

New company BliNK Biomedical created to focus on antibody discovery

Read More

Anthera Pharmaceuticals licenses Japanese rights to blisibimod to Zenyaku Kogyo

Read More

New study evaluates dabigatran etexilate to prevent recurrent embolic stroke of undetermined source

Read More

NEOD-001 given FDA fast track designation for AL amyloidosis

Read More

IND accepted for ADXS-HPV plus MEDI-4736 in HPV-associated cancers

Read More

Neovacs' phase IIb trial of TNF-Kinoid in rheumatoid arthritis misses endpoint

Read More

FDA approves Signifor LAR for acromegaly

Read More

ViiV Healthcare applies for Japanese approval of dolutegravir/abacavir/lamivudine

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 18, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • GLP-1 capsule

    Maintenance, man: Lilly’s phase III weight trial hits goals

    BioWorld
    Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
  • Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

    AI drug developer Insilico to raise $292 million in Hong Kong IPO

    BioWorld
    Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing